Animal study demonstrates that Pleurotus ostreatus reduces blood glucose and improves lipid profiles in diabetic rats, highlighting its therapeutic potential.
Oyster Mushroom (Pleurotus ostreatus), an edible mushroom, is traditionally being used as a curing. However, hypoglycemic as well as antidyslipidemic effects on methanolic and ethyl acetate extracts of oyster mushroom in streptozotocin-treated diabetic rat model was not investigated yet. Here, we investigated that oral administration of 200 mg/kg oyster mushroom for 30 days were estimated through evaluating the fasting blood glucose level and blood lipid profile of diabetic rat. The results from our studies explained that P. ostreatus oyster mushroom considerably decreased blood glucose level initiated after treatment on second week. However, oyster mushroom was significantly reduced in plasma triglycerides (TG), total cholesterol (TC), as well as low-density lipoprotein-cholesterol (LDL-C). Additionally, high density lipoprotein-cholesterol (HDL-C) was enhanced by the treatment of oyster mushroom. Therefore, the current study suggests that P. ostreatus has antihyperglycemic and antidyslipidemic effect on diabetic rat model. [ J Adv Biotechnol Exp Ther 2020; 3(1.000): 49-55]
No takes yet. Share an insight, caveat, or question.
Karim et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: